What is it about?
A critical appraisal of the importance of alternated therapies based on inhibiting the activity of chymase in the treatment of cardiovascular disease.
Featured Image
Why is it important?
Research now documents that a limited therapeutic efficacy of current treatments based on inhibiting angiotensin converting enzyme or blocking angiotensin II receptors in terms of preventing the occurrence of heart attacks, heart failure, and kidney disease. Their limited efficacy may , in part reflect a differential mechanisms for angiotensin Ii production between animals and humans.
Perspectives
A renewed effort to achieve better therapeutic outcomes through the use of chymase inhibitors.
Carlos M Ferrario
Wake Forest University
Read the Original
This page is a summary of: Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010–2018), Expert Opinion on Therapeutic Patents, October 2018, Taylor & Francis,
DOI: 10.1080/13543776.2018.1531848.
You can read the full text:
Contributors
The following have contributed to this page
